Q-omics provides the consensus-scored ZNF285B profile across patient tissues and cancer cell-line models. ZNF285B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF285B is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, ZNF285B RNA expression shows 18,457 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, LIHC, and UVM as cancer lineages where ZNF285B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF285B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF285B survival associations across molecular data types. ZNF285B RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF285B RNA expression–survival associations across cancer types. High ZNF285B expression shows unfavorable associations in MESO, LGG and LUSC, but favorable associations in HNSC, SKCM and GBM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF285B RNA expression.
This table summarizes ZNF285B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF285B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF285B shows lower tumor expression in THCA and higher tumor expression in LIHC, KICH, BLCA, STAD and LUAD. The LIHC box plot shows higher ZNF285B RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .003).
This table shows molecular features associated with ZNF285B in patient tissues and cancer cell lines. In patient samples, ZNF285B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
